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Abstract
Mucormycosis is a rare oportunistic infection typically described in  diabetic patients with a ketoacidotic status, as 
well as neutropenic patients. The infection is caused by a group of saprophytic fungi of the class Phycomicetes, being 
the most frequent ones the Rhizomucor, Rhizopus and Mucor. Its hystological findings include vascular trombosis 
and tissue necrosis, predominantly in the rino-orbito-cerebral area. 
Even though the frequency of presentation is very low, given its rapid evolution and severe consequences which in-
clude a high mortality rate, it is very important to be aware of the main features of the disease and treat it promptly. 
Although the diagnosis is based on the high clinical suspect, the computed tomography (CT) and the magnetic reso-
nance image (MRI) plays an important role in determining the extension. The patients should receive treatment in 
a reference hospital so that a multidisciplinary approach is ensured.
In this sense, we present a case of rhino-orbito-cerebralmucormycosis in a diabetic patient, recently treated in our 
Department. A comprehensive review of the literature has been performed to update the physiopathology and diag-
nosis. Finally, we describe the different treatment options focusing in the surgical approach, as well as the medical 
treatment with amphotericine and posaconzole
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Introduction
 Mucormycosis (also known as zygomycosis or phycomyco-
sis), was first described by Paulltauf in 1885 (1). Typically 
developed by poorly controlled diabetic patients, this 
opportunistic infection is characterized by a very acute 
onset. It produces vascular thrombosis and tissue necrosis 
and the most frequent form is the rhino-orbito-cerebral 
(2). It must be ruled out in every patient with risk factors 
(ketoacidotic patients and haematologic malignancies) and 
signs or symptoms affecting  the nose, paranasal sinuses, 
orbit or central nervous system (CNS) (2,3). The prognosis 
is poor, with severe sequelae and high mortality even in 
patients with a prompt diagnosis and  correct treatment.
Publication Types: Case Reports
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Case Report
The patient was a 75 year-old male with diabetes mellitus 
(DM) treated with oral antidiabetics (metformin, glicipi-
de), elevated blood pressure controlled by drug therapy, 
inhaler therapy for his chronic bronchitis (teophylline), 
and benign prostatic hypertrophy. He was attended in 
his local hospital for respiratory failure due to relapse of 
his pulmonary disease. He was prescribed  prednisone 
and doxycycline. Five days later he developed unspecific 
discomfort in his left eye and poor glucemic control. 
The laboratory findings showed 12.600 WBC/mm3 (90% 
neutrophiles, 3% lymphocytes, 5% monocytes), blood 
glucose level 420 mg /dl, urea 18 mg/dl, creatinine 0.6 
mg/dl, sodium 132 mmol/l, potassium 3.6 mmol/l, liver 
enzymes and coagulation values without alteration. The 
venous gasometry revealed acidosis (pH 7.23, HCO3 14 
mmol/l). The urine test determined glucose greater than 
1000 mg/ml, density greater than 1030, proteinuria  30 
mg /dl and cetonic bodies greater than 80 mg/dl. He was 
evaluated by the ophthalmologist because of his left eye 
pain and chemosis, and acute conjunctivitis was diagno-
sed. Finally he was admitted to control the glucemia. Two 
days later, in spite of the regulated blood glucose levels 
and the correction of the acidosis, the ocular pain and 
chemosis worsened and proptosis and motility restriction 
of the affected eye developed. A serohematic suppuration 
from his left nostril appeared, and a complete necrosis of 
the left hemipalate was evident (Fig. 1). As mucormycosis 
was suspected,  intravenous amphotericin B therapy (3 
mg/ kg day) was established, and an incisional biopsy 
was taken under local anaesthesia.  The histopathologic 
study was consistent with mucormycosis. The computed 
tomography (CT) study showed palatal involvement, left 
nasal fossa, left maxillary and ethmoid sinus and left orbit 
occupation (Fig. 2). The patient was then referred to La 
Paz University Hospital because of the extension of the 
infection. Eight days later, on arrival  at our hospital, the 
patient showed complete left palate necrosis, serohematic 
suppuration with abundant necrotic tissue from his left 
nostril, severe left ocular involvement with reduced visual 
acuity, pupilar afferent defect and severe chemosis and 
ophtalmoplegia in his left eye. An emergency surgical 
resection was undertaken by the maxillofacial surgeon, 
neurosurgeon, ophthalmologist and ENT surgeon. A com-
plete left maxillectomy with orbit exenteration extended to 
the infratemporal fossa was performed. The sphenoid and 
frontal sinuses were endoscopically examined and found 
to be free from disease. A small cephalorachidian liquid 
fistula was discovered and successfully treated intraopera-
tively with local flaps and dura mater sealers. The defect 
was packed with terramicine gauze, as the topical use of 
amphotericin B is banned in Spain. The postoperative 
period was uneventful, with good glucemic and renal 
control, and administration of 5 mg/ kg day of liposomal 
amphotericin. Several biopsies were performed, all of 
them negative for fungus. The MRI examinations showed 
no  new fungus extension. After 37 days of intravenous 
treatment with amphotericin B, the patient was discharged 
and sent to his local hospital to continue the parenteral 
treatment. The final microbiologic exam performed in 
the National Microbiologic Center detected a Rhizopus 
Oryzae infection (Fig. 3)
Fig. 3. Lactophenol blue stain.
Fig. 1. Complete necrosis of the 
left hemipalate.
Fig. 2. The computed tomography (CT) study showed palatal 
involvement, left nasal fossa, left maxillary and ethmoid sinus 
and left orbit occupation
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The microsurgical reconstruction was delayed to ensure 
the patient was free from disease. An obturator was elabo-
rated so the patient was able to eat and speak, enjoying a 
good quality of life and avoiding tissue scarring retraction. 
Unfortunately, before the reconstruction was performed, 
the patient presented a cardiac arrest and died.
Discussion
Mucormycosis is caused by fungi in the phycomycetos 
order, the main pathogens belong to the  Rhizomucor, 
Rhizopus, Absidia and Mucor species, but we can find 
many different fungi (Cunninghamella, Saksenaea, Syn-
cephalastrum, Cokeromyces, Mortierella).The few cases 
reported by the Apophytomices in the medical literature 
usually correspond to healthy individuals with traumatic 
inoculation. This fungus usually acts as an opportunistic 
pathogen. It is present in soil, decaying organic debris and 
bread moulds but only  infects  compromised subjects. 
The principal predisposing factors are  diabetes mellitus 
(specially with acidosis) and hematologic malignances 
with neutropenia. It has been established  that high glu-
cose concentrations enhance fungus growth. Evenmore, 
cetoacidotic patient serum is not able to stop the fungus 
growth, maybe because it can not chelate the iron, and this 
iron excess is used by the fungus to produce rhizoferrin. 
As the cell responsible for the defence against fungus is 
the neutrophile, their alteration in number or function in 
hematologic malignancies leads to an increased risk of 
infection. Other identified risk factors are chronic ste-
roid treatment, organ transplant, chemotherapy, chronic 
renal insufficiency, ferrum intoxication (desferoxamine 
treatment in dialyzed patients), burn patients. However, 
it is not frequent in immunodeficiency (HIV) patients as 
they suffer a lymphocitic immunity disorder. There are 
also cases related to tooth extraction, but it is not easy 
to determine if  the extraction site was the entrance point 
for the infection or if  the infection caused the toothache 
that led to the extraction. There  are occasionally some 
cases without identified risk factors, usually related to 
Apophytomices in traumatic healthy patients.
We can divide this entity into 6 forms: rhino-orbito-cere-
bral, respiratory, gastrointestinal, cutaneous, widespread 
and mixed. The most frequent one is the rhino-orbito-
cerebral, with or without CNS involvement, but almost 
always with ocular damage. No patient to patient spread 
has been reported, the dissemination occurs via inhala-
tion of spores. In healthy subjects, these spores would 
be fagocitated by the polymorphonuclear leukocytes. 
On the other hand, in the risk patient the rapid growth 
in the nasal fosa is usually silent, with nasal obstruction 
and rhinorrea. Only in advanced disease with paranasal 
sinus, orbit or CNS involvement  are the symptoms  more 
specific. The necrotic eschar is very suggestive but it only 
appears in 20-40% of the patients, and is considered a 
bad prognosis sign.
The orbit extension occurs via the nasolacrimal duct, me-
dial wall dehiscences or the anterior and posterior ethmoid 
orifices. The CNS is affected through the orbit apex, the 
orbit vessels or the cribiform plate. The fungus adheres 
to the internal elastic lamina of the blood vessels, leading 
to ischemia and necrosis. Perineural spread through the 
trigeminal branches has also been described.
Cavernous sinus thrombosis may be due to a complicated 
mucormycosis or to a bacterial septic thrombosis,  the 
former being more acute. The CNS injury is produced by 
direct extension or internal carotid artery thrombosis.
This infection must be suspected in every patient with risk 
factors and signs or symptoms referring to nasal fosa, 
paranasal sinuses, orbit and CNS, even with inespecific 
disturbance. The diagnosis is confirmed by the histologic 
and microbiologic studies, obtained either by open biopsy 
or fine needle aspiration (FNA) . In the event of negative 
biopsy in a case of  high clinical suspicion, the biopsy 
should be repeated to include deeper tissues and larger 
vessels to identify the fungus in the lumen. Hematoxilin-
eosin, periodic acid-Schiff (PAS) and Gomori silver stains 
are usually employed. The optic microscopy shows large 
nonsepted hyphae that tend to branch at right angles. 
However, the Aspergyllus shows septated hyphae with a 
more acute branching pattern. Fungus culture is difficult 
and requires selective media. The extension study is based 
on CT and  magnetic resonance image (MRI ) studies, 
determining the involvement of sinuses, orbits and CNS. 
It must be taken  into account that bone erosion is a late 
sign. The MRI gives  a better visualization of the CNS, 
perineural invasion and vascular obstruction. It is the  pre-
ferred choice because of the coincident use of nephrotoxic 
drugs and the presence of compromised renal function.
These patients should always be managed in a third le-
vel  hospital, as they need evaluation and treatment by 
a multidisciplinary team (maxillofacial surgeon, ENT 
specialist, ophthalmologist, neurosurgeon, intensive care 
unit, infectious disease department and endocrinology 
service). It is essential to correct the acidosis status, to 
regulate the blood glucose levels, rehydrate the patient and 
correct the electrolithic disbalance. Immunosuppressor 
therapy as well as corticosteroids should be immediately 
discontinued and treatment with amphotericin B should 
be commenced.
Amphotericin B binds to the cellular membrane sterols, 
altering their permeability. Its numerous side effects con-
dition an initial low dose with progressive increase if  well 
tolerated. The most frequent ones include chills, fever ,bac-
kache, chest pain, dyspnea, bronchospasm, tachycardia, 
hypotension, rash, nausea and vomiting, abdominal pain, 
diarrhea, phlebitis…Some authors recommend premedi-
cation with diphenhydramine, petidine, paracetamol and 
Cortisone to avoid these side effects. Nowadays, we use 
liposomal amphotericin B, that although more expensive 
has less renal toxicity, fewer adverse effects, and a better 
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solubility in the CNS. Hence the dose can be safely in-
creased. The initial dose is 1 mg /kg day, which can be 
increased to 3 or even 5 mg /kg day. The 5 mg dose has not 
shown better results than the 3 mg dose in patients with 
aspergyllus infections but is the dose of choice reported 
by many authors in mucor infections. Furthermore, some 
physicians recommend 15 mg /kg day. Renal function as 
well as potassium and magnesium must be rigorously 
monitored  during the treatment, that usually lasts for 3 
to 7 months.
Surgical treatment is always necessary, with extended 
resection until bleeding tissue is found. Efforts to save 
the ocular globe with conservative resections usually lead 
to a delayed enucleation and worsening of the patient. 
We must ensure the paranasal sinus drainage. It is quite 
frequent to perform repeated resections of small residual 
fungus foci from the margins of the wound during the 
postoperative period; in these cases, the frozen section 
analysis is extremely useful. There is agreement in the use 
of amphotericin irrigation of the surgical field, as well as 
the amphotericin embedded gauze. The aim is to ensure 
the drug biodisponibility in the surgical field, where the 
vascularitation is compromised because of the thrombo-
sis. Surgical reconstruction is usually deferred until the 
infection is completely resolved.
The fungistatic and angiogenic effects of hyperbaric oxy-
gen could enhance the effect of amphotericin B and im-
prove the vascularization. Its value is not well established 
but it is thought to improve prognosis in CNS cases, with 
the use of 100% oxygen for 90 to 180 minutes at pressures 
from 2 to 2.5 atmospheres with 1 or 2 exposures daily for 
a total of 40 treatments.
The use of other drugs has been reported, such as the 
combination of rifampicin and amphotericin. In the US, 
posaconazole is employed in amphotericin resistance or 
intolerance, with good results. It can be administered 
orally, and is well tolerated with a high response rate. We 
can also find promising results with the use of granulo-
cyte-monocyte colony stimulating factor in patients with 
hematologic diseases.
The follow up is based on clinical examinations as well 
as weekly MRI. Some authors recommend repeated 
biopsies. In the last 50 years, the prognosis has improved 
dramatically, with a mortality rate of 85% in 1960  that has 
now decreased to 30-35% . The most important prognosis 
factor is delayed diagnosis and treatment. Functional and 
aesthetic sequelae are to be expected in the rhinocerebral 
forms.
Conclusion
A prompt diagnosis is crucial to improve the survival and 
reduce the sequela of patients with rhinoorbitocerebral 
mucormycosis. The treatment must focus in correcting 
the general status, appropiate antimicrobian treatment 
and surgical resection. The gold standard of the medical 
treatment is  amphotericin B, although the new antifun-
gic generation is obtaining promising results with fewer 
adverse effects.
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